Ghosh S, Champlin R E, Ueno N T, Anderlini P, Rolston K, Raad I, Kontoyiannis D, Jacobson K, Luna M, Tarrand J, Whimbey E
Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Bone Marrow Transplant. 2001 Aug;28(3):271-5. doi: 10.1038/sj.bmt.1703131.
Scant data are available concerning the impact and response to therapy of respiratory syncytial virus (RSV) infections in patients undergoing autologous blood and marrow transplantation (BMT) for breast cancer. During eight winter seasons from 1992-1993 to 1999-2000, nine (4%) of 249 such patients were hospitalized with RSV infections. Six patients, including all five patients who were early post transplant in the pre-engraftment period, developed pneumonia and were treated with a combination of aerosolized ribavirin and IVIG. Among five patients with pneumonia in whom therapy was initiated prior to respiratory failure, one (20%) died. The sixth patient, in whom therapy was initiated after respiratory failure developed, also died. In total, two (1%) patients, both of whom were in the pre-engraftment period, died of progressive pneumonia. In conclusion, RSV is a significant cause of life-threatening pneumonia in autologous BMT recipients with breast cancer during the early post-transplant period, and accounted for a substantial portion of the overall transplant-related mortality, which in recent years has been minimal.
关于接受自体血液和骨髓移植（BMT）治疗乳腺癌的患者中呼吸道合胞病毒（RSV）感染的影响及对治疗的反应，可用数据很少。在1992 - 1993年至1999 - 2000年的八个冬季，249例此类患者中有9例（4%）因RSV感染住院。6例患者，包括移植后早期处于植入前期的所有5例患者，发生了肺炎，并接受了雾化利巴韦林和静脉注射免疫球蛋白的联合治疗。在呼吸衰竭前开始治疗的5例肺炎患者中，1例（20%）死亡。第6例患者在呼吸衰竭发生后开始治疗，也死亡。总共有2例（1%）患者死于进行性肺炎，这2例患者均处于植入前期。总之，RSV是自体BMT治疗乳腺癌患者移植后早期危及生命的肺炎的重要病因，并且在近年来总体移植相关死亡率已降至最低的情况下，仍占相当大的比例。
